Triple-negative breast cancer (TNBC) accounts for 10–20% of all breast cancers and is characterized by the absence of estrogen receptor, progesterone receptor, and HER2 amplification, leading to poorer prognoses compared to other subtypes [2,3]. This evidence concerns the gene ERBB2 and breast cancer.